Antitumor effect of CDK inhibitor in mesothelioma

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10283
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: Hyogo Medical University
• Principal Investigator: Masaki Hashimoto 兵庫医科大学, 医学部, 助教 (40461074)
• Co-Investigator(Kenkyū-buntansha): 長谷川 誠紀 兵庫医科大学, 医学部, 教授 (10252438) ; 近藤 展行 兵庫医科大学, 医学部, 講師 (50402889) ; 松本 成司 兵庫医科大学, 医学部, 講師 (60412011) ; 多久和 輝尚 兵庫医科大学, 医学部, 助教 (00412049) ; 黒田 鮎美 兵庫医科大学, 医学部, 助教 (90642570) ; 中道 徹 兵庫医科大学, 医学部, 病院助手 (70748384) ; 土井 啓至 兵庫医科大学, 医学部, 非常勤講師 (50529047)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 中皮腫

Outline of Final Research Achievements

The WST-8 was used to evaluate the anti-tumor effects of CDK inhibitors（Palbociclib, Abemaciclib）in malignant pleural mesothelioma cell lines. Both agents inhibited the proliferation of cell lines in a concentration-dependent manner. The combined Abemaciclib and radiotherapy effects were assessed by measuring cell cycles, using the BrdU Flow Kit. Abemaciclib administration and radiotherapy application both resulted in more S phase reduction than in the control; the combined use of Abemaciclib and radiotherapy resulted in further S phase reduction. An animal experiment also revealed that although use of Abemaciclib alone resulted in weaker anti-tumor effects than radiotherapy alone, the combined use of Abemaciclib and radiotherapy completely suppressed subcutaneous tumor expansion.

Free Research Field

呼吸器外科